CClinicalTrials.gg
CompletedNCT03313232Updated Apr 10, 2018

Low Dose Exposure to Oxidized R-limonene - A Repeated Open Application Test (ROAT) Study

An interventional study of ROAT with oxidized R-limonene at 1%, 0.3% and 0.1% and ROAT with oxidized R-limonene at 1% in Allergic Contact Dermatitis Due to Cosmetics, sponsored by Herlev and Gentofte Hospital. Completed at 2 sites in 2 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-04-10.

Sponsored by Herlev and Gentofte Hospital · Not applicable, Interventional, and Diagnostic

Phase
Not applicable
Study type
Interventional
Enrollment
48
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study evaluates the clinical and molecular effect of daily exposure to low doses of the fragrance contact allergen oxidized R-limonene. Three groups of participants are included: 1) Patients with a previous positive patch test to oxidized R-Limonene, 2) patients with a previous doubtful patch test to oxidized R-limonene and 3) healthy controls with no contact allergy to oxidized R-limonene

02

Conditions studied

  • Allergic Contact Dermatitis Due to Cosmetics
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Positive patch test (at least one reading) or doubtful patch test (at least two readings) to oxidized R-limonene 3% pet. (with 0.33% hydroperoxides content) according to international guidelines, within the last five years.
  • Aged 18 years or older
  • Received written and verbal information on the study.
  • Signed written consent form.

Exclusion criteria

Exclusion Criteria:

  • Active eczema in test areas.
  • Pregnancy or breast feeding.
  • Treatment with topical corticosteroids or other immune-suppressants on/near test areas within two weeks prior to study start.
  • Systemic immune-suppressant treatment within seven days prior to study start.
  • UV exposure of test areas within three weeks prior to study start.
  • Unable to cooperate or communicate with the investigators.
04

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Fragrance allergic patients

    Patients with a previous positive patch test to oxidized R-Limonene. Patients will have an initial patch test dilution series with oxidized R-limonene performed on the back followed by twice daily exposure to oxidized R-limonene at three different concentrations and a vehicle control on the forearms for up to three weeks.

    Other: ROAT with oxidized R-limonene at 1%, 0.3% and 0.1%

  • Experimental
    Possible fragrance allergic patients

    Patients with a previous doubtful patch test to oxidized R-limonene. Patients will have an initial patch test dilution series with oxidized R-limonene performed on the back followed by twice daily exposure to oxidized R-limonene at three different concentrations and a vehicle control on the forearms for up to three weeks.

    Other: ROAT with oxidized R-limonene at 1%, 0.3% and 0.1%

  • Experimental
    Healty controls

    Healthy controls with no contact allergy to oxidized R-limonene. Healthy controls will have en initial diagnostic patch test with oxidized R-limonene performed followed by twice daily exposure to oxidized R-limonene at one concentration and a vehicle control on the forearms for up to three weeks.

    Other: ROAT with oxidized R-limonene at 1%

Interventions

  • OtherROAT with oxidized R-limonene at 1%, 0.3% and 0.1%

    A twice daily repeated open application test (ROAT) study for up to three weeks of exposure to oxidized R-limonene at 1%, 0.3% and 0.1% concentrations

  • OtherROAT with oxidized R-limonene at 1%

    A twice daily repeated open application test (ROAT) study for up to three weeks of exposure to oxidized R-limonene at a 1% concentration

05

What researchers measure

Primary outcomes

  1. Positive ROAT (minimum score of 5)

    Proportion (%) of participants with a positive ROAT

    Time frame: Day (D) 21

Secondary outcomes

  1. Minimal eliciting concentration (MEC)

    Threshold concentration for a positive patch test

    Time frame: Day (D) 7

Other outcomes

  1. Epidermal inflammatory markers

    Levels of inflammatory markers (e.g. IL-1beta) from tape stripping of ROAT test areas

    Time frame: Positive ROAT or Day (D) 21

06

Study locations

2 sites
  • Department of Dermatology and Allergy, Gentofte University Hospital
    Hellerup, DK 2900, Denmark
  • Department of Occupational and Environmental Dermatology, Sahlgrenska University Hospital
    Göteborg, SE 41345, Sweden
07

Registry details

Key details

Study ID
NCT03313232
Lead sponsor
Herlev and Gentofte Hospital
Collaborators
University of Copenhagen, Sahlgrenska University Hospital, Göteborg University
Responsible party
Niels Højsager Bennike (Principal investigator, Herlev and Gentofte Hospital) — Principal investigator
First posted
Oct 18, 2017
Start date
Oct 10, 2017
Primary completion
Apr 9, 2018
Completion
Apr 9, 2018
Last update
Apr 10, 2018

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion